Exagen PE Ratio 2019-2025 | XGN
Current and historical p/e ratio for Exagen (XGN) from 2019 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Exagen PE ratio as of February 10, 2026 is 0.00.
| Exagen PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-02-11 | 3.30 | 0.00 | |
| 2025-09-30 | 10.99 | $-0.92 | 0.00 |
| 2025-06-30 | 6.98 | $-0.89 | 0.00 |
| 2025-03-31 | 3.59 | $-0.84 | 0.00 |
| 2024-12-31 | 4.10 | $-0.83 | 0.00 |
| 2024-09-30 | 3.09 | $-0.94 | 0.00 |
| 2024-06-30 | 1.82 | $-0.97 | 0.00 |
| 2024-03-31 | 1.59 | $-1.09 | 0.00 |
| 2023-12-31 | 1.99 | $-1.34 | 0.00 |
| 2023-09-30 | 2.42 | $-1.86 | 0.00 |
| 2023-06-30 | 2.90 | $-2.02 | 0.00 |
| 2023-03-31 | 2.43 | $-2.52 | 0.00 |
| 2022-12-31 | 2.40 | $-2.68 | 0.00 |
| 2022-09-30 | 2.71 | $-2.27 | 0.00 |
| 2022-06-30 | 5.74 | $-2.22 | 0.00 |
| 2022-03-31 | 8.03 | $-1.82 | 0.00 |
| 2021-12-31 | 11.63 | $-1.70 | 0.00 |
| 2021-09-30 | 13.60 | $-1.55 | 0.00 |
| 2021-06-30 | 14.99 | $-1.47 | 0.00 |
| 2021-03-31 | 17.50 | $-1.36 | 0.00 |
| 2020-12-31 | 13.20 | $-1.32 | 0.00 |
| 2020-09-30 | 10.84 | $-1.32 | 0.00 |
| 2020-06-30 | 12.41 | $-12.27 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.079B | $0.056B |
| Exagen Inc. is engaged in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases. It developed and commercialises testing products under AVISE brand. Exagen Inc. is based in Vista, California. | |||